Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians.

Francesco Passiglia, Marta Castiglia, Konstantinos Papadimitriou, Marta Castiglia, Francesco Passiglia, Marcin Ostrowski, Ana Dolcan, Lúcia Farracho, Tereza Ondøichová, Patrick Pauwels, Christian Rolfo, Roy Remmen

Risultato della ricerca: Article

15 Citazioni (Scopus)

Abstract

In the past decade the advent of target therapy has led to a silent revolution in the treatment of lung cancer. Thanks to the specificity of their target, new tailored drugs are able to achieve a larger benefit and lower toxicity and provide better quality of life than cytotoxic drugs in a limited number of patients, selected by molecular profile. Nowadays, the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib, and the anaplastic lymphoma kinase inhibitor crizotinib, are targeted agents approved for treatment of non-small-cell lung cancer. Family physicians play an important role in the treatment, detection, and management of common toxicities and in providing emotional support. Therefore this review integrates molecular profile assessment with evidence of the efficacy and toxicity of tyrosine kinase inhibitors to provide an updated overview of the treatment of non-small-cell lung cancer, which radically changed after the advent of targeted therapies. It also aims to promote a more intensive and interactive collaboration between specialists and family physicians in the management of all phases of cancer care.
Lingua originaleEnglish
pagine (da-a)124-133
Numero di pagine10
RivistaJournal of the American Board of Family Medicine
Volume28
Stato di pubblicazionePublished - 2015

Fingerprint

Family Physicians
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Therapeutics
Epidermal Growth Factor Receptor
Pharmaceutical Preparations
Quality of Life
Neoplasms

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health
  • Family Practice

Cita questo

Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians. / Passiglia, Francesco; Castiglia, Marta; Papadimitriou, Konstantinos; Castiglia, Marta; Passiglia, Francesco; Ostrowski, Marcin; Dolcan, Ana; Farracho, Lúcia; Ondøichová, Tereza; Pauwels, Patrick; Rolfo, Christian; Remmen, Roy.

In: Journal of the American Board of Family Medicine, Vol. 28, 2015, pag. 124-133.

Risultato della ricerca: Article

Passiglia, F, Castiglia, M, Papadimitriou, K, Castiglia, M, Passiglia, F, Ostrowski, M, Dolcan, A, Farracho, L, Ondøichová, T, Pauwels, P, Rolfo, C & Remmen, R 2015, 'Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians.', Journal of the American Board of Family Medicine, vol. 28, pagg. 124-133.
Passiglia, Francesco ; Castiglia, Marta ; Papadimitriou, Konstantinos ; Castiglia, Marta ; Passiglia, Francesco ; Ostrowski, Marcin ; Dolcan, Ana ; Farracho, Lúcia ; Ondøichová, Tereza ; Pauwels, Patrick ; Rolfo, Christian ; Remmen, Roy. / Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians. In: Journal of the American Board of Family Medicine. 2015 ; Vol. 28. pagg. 124-133.
@article{a864021d8dc34c92991b74619d21f814,
title = "Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians.",
abstract = "In the past decade the advent of target therapy has led to a silent revolution in the treatment of lung cancer. Thanks to the specificity of their target, new tailored drugs are able to achieve a larger benefit and lower toxicity and provide better quality of life than cytotoxic drugs in a limited number of patients, selected by molecular profile. Nowadays, the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib, and the anaplastic lymphoma kinase inhibitor crizotinib, are targeted agents approved for treatment of non-small-cell lung cancer. Family physicians play an important role in the treatment, detection, and management of common toxicities and in providing emotional support. Therefore this review integrates molecular profile assessment with evidence of the efficacy and toxicity of tyrosine kinase inhibitors to provide an updated overview of the treatment of non-small-cell lung cancer, which radically changed after the advent of targeted therapies. It also aims to promote a more intensive and interactive collaboration between specialists and family physicians in the management of all phases of cancer care.",
author = "Francesco Passiglia and Marta Castiglia and Konstantinos Papadimitriou and Marta Castiglia and Francesco Passiglia and Marcin Ostrowski and Ana Dolcan and L{\'u}cia Farracho and Tereza Ond{\o}ichov{\'a} and Patrick Pauwels and Christian Rolfo and Roy Remmen",
year = "2015",
language = "English",
volume = "28",
pages = "124--133",
journal = "Journal of the American Board of Family Medicine",
issn = "1557-2625",
publisher = "American Board of Family Medicine",

}

TY - JOUR

T1 - Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians.

AU - Passiglia, Francesco

AU - Castiglia, Marta

AU - Papadimitriou, Konstantinos

AU - Castiglia, Marta

AU - Passiglia, Francesco

AU - Ostrowski, Marcin

AU - Dolcan, Ana

AU - Farracho, Lúcia

AU - Ondøichová, Tereza

AU - Pauwels, Patrick

AU - Rolfo, Christian

AU - Remmen, Roy

PY - 2015

Y1 - 2015

N2 - In the past decade the advent of target therapy has led to a silent revolution in the treatment of lung cancer. Thanks to the specificity of their target, new tailored drugs are able to achieve a larger benefit and lower toxicity and provide better quality of life than cytotoxic drugs in a limited number of patients, selected by molecular profile. Nowadays, the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib, and the anaplastic lymphoma kinase inhibitor crizotinib, are targeted agents approved for treatment of non-small-cell lung cancer. Family physicians play an important role in the treatment, detection, and management of common toxicities and in providing emotional support. Therefore this review integrates molecular profile assessment with evidence of the efficacy and toxicity of tyrosine kinase inhibitors to provide an updated overview of the treatment of non-small-cell lung cancer, which radically changed after the advent of targeted therapies. It also aims to promote a more intensive and interactive collaboration between specialists and family physicians in the management of all phases of cancer care.

AB - In the past decade the advent of target therapy has led to a silent revolution in the treatment of lung cancer. Thanks to the specificity of their target, new tailored drugs are able to achieve a larger benefit and lower toxicity and provide better quality of life than cytotoxic drugs in a limited number of patients, selected by molecular profile. Nowadays, the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib, and the anaplastic lymphoma kinase inhibitor crizotinib, are targeted agents approved for treatment of non-small-cell lung cancer. Family physicians play an important role in the treatment, detection, and management of common toxicities and in providing emotional support. Therefore this review integrates molecular profile assessment with evidence of the efficacy and toxicity of tyrosine kinase inhibitors to provide an updated overview of the treatment of non-small-cell lung cancer, which radically changed after the advent of targeted therapies. It also aims to promote a more intensive and interactive collaboration between specialists and family physicians in the management of all phases of cancer care.

UR - http://hdl.handle.net/10447/105901

UR - http://www.jabfm.org

M3 - Article

VL - 28

SP - 124

EP - 133

JO - Journal of the American Board of Family Medicine

JF - Journal of the American Board of Family Medicine

SN - 1557-2625

ER -